Merck & Co. Inc. (MRK)

$129.37

-0.83

(-0.64%)

Market is closed - opens 7 PM, 14 Jun 2024
star icon

Merck & Co Inc is a pharmaceutical company that develops and sells prescription drugs in various therapeutic areas, including oncology, vaccines, and infectious diseases.

Insights on Merck & Co. Inc.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 15.96B → 14.63B (in $), with an average decrease of 4.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 4.74B → -1.22B (in $), with an average decrease of 62.9% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 94.6% return, outperforming this stock by 76.2%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 287.0% return, outperforming this stock by 216.3%

Performance

  • $128.60
    $130.12
    $129.37
    downward going graph

    0.6%

    Downside

    Day's Volatility :1.17%

    Upside

    0.58%

    downward going graph
  • $97.81
    $133.10
    $129.37
    downward going graph

    24.4%

    Downside

    52 Weeks Volatility :26.51%

    Upside

    2.8%

    downward going graph

Returns

PeriodMerck & Co. Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
6.58%
-0.3%
-0.8%
6 Months
21.56%
7.4%
4.4%
1 Year
18.37%
11.0%
13.2%
3 Years
72.56%
17.3%
12.3%

Highlights

Market Capitalization
333.9B
Book Value
$15.94
Dividend Share
2.96
Dividend Yield
2.34%
Earnings Per Share (EPS)
0.89
PE Ratio
148.13
PEG Ratio
0.1
Wall Street Target Price
142.98
Profit Margin
3.76%
Operating Margin TTM
42.47%
Return On Assets TTM
10.26%
Return On Equity TTM
5.31%
Revenue TTM
61.4B
Revenue Per Share TTM
24.22
Quarterly Revenue Growth YOY
8.9%
Gross Profit TTM
42.1B
EBITDA
21.2B
Diluted Eps TTM
0.89
Quarterly Earnings Growth YOY
0.69
EPS Estimate Current Year
8.65
EPS Estimate Next Year
9.95
EPS Estimate Current Quarter
1.87
EPS Estimate Next Quarter
2.16

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 31 Wall street analysts offering stock ratings for Merck & Co. Inc.(by analysts ranked 0 to 5 stars)
Based on 31 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
27
27
27
Hold
4
5
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 10.52%

Current $129.37
Target $142.98

Company Financials

FY18Y/Y Change
Revenue
42.3B
↑ 5.41%
Net Income
6.2B
↑ 142.21%
Net Profit Margin
14.71%
↑ 8.31%
FY19Y/Y Change
Revenue
46.8B
↑ 10.75%
Net Income
9.8B
↑ 58.25%
Net Profit Margin
21.01%
↑ 6.3%
FY20Y/Y Change
Revenue
48.0B
↑ 2.46%
Net Income
7.1B
↓ 28.2%
Net Profit Margin
14.72%
↓ 6.29%
FY21Y/Y Change
Revenue
48.7B
↑ 1.48%
Net Income
13.0B
↑ 84.65%
Net Profit Margin
26.79%
↑ 12.07%
FY22Y/Y Change
Revenue
59.3B
↑ 21.72%
Net Income
14.5B
↑ 11.27%
Net Profit Margin
24.49%
↓ 2.3%
FY23Y/Y Change
Revenue
59.9B
↑ 0.99%
Net Income
365.0M
↓ 97.49%
Net Profit Margin
0.61%
↓ 23.88%
Q4 FY22Q/Q Change
Revenue
13.8B
↓ 7.55%
Net Income
3.0B
↓ 7.11%
Net Profit Margin
21.81%
↑ 0.1%
Q1 FY23Q/Q Change
Revenue
14.5B
↑ 4.75%
Net Income
2.8B
↓ 6.5%
Net Profit Margin
19.47%
↓ 2.34%
Q2 FY23Q/Q Change
Revenue
15.0B
↑ 3.78%
Net Income
-6.0B
↓ 311.8%
Net Profit Margin
-39.74%
↓ 59.21%
Q3 FY23Q/Q Change
Revenue
16.0B
↑ 6.17%
Net Income
4.7B
↓ 179.41%
Net Profit Margin
29.73%
↑ 69.47%
Q4 FY23Q/Q Change
Revenue
14.6B
↓ 8.34%
Net Income
-1.2B
↓ 125.84%
Net Profit Margin
-8.38%
↓ 38.11%
Q1 FY24Q/Q Change
Revenue
14.6B
↑ 0.0%
Net Income
-1.2B
↑ 0.0%
Net Profit Margin
-8.38%
↑ 0.0%
FY18Y/Y Change
Total Assets
82.6B
↓ 5.96%
Total Liabilities
55.8B
↑ 4.6%
FY19Y/Y Change
Total Assets
84.4B
↑ 2.13%
Total Liabilities
58.4B
↑ 4.74%
FY20Y/Y Change
Total Assets
91.6B
↑ 8.52%
Total Liabilities
66.2B
↑ 13.34%
FY21Y/Y Change
Total Assets
105.7B
↑ 15.4%
Total Liabilities
67.4B
↑ 1.89%
FY22Y/Y Change
Total Assets
109.2B
↑ 3.28%
Total Liabilities
63.1B
↓ 6.43%
FY23Y/Y Change
Total Assets
106.7B
↓ 2.28%
Total Liabilities
69.0B
↑ 9.41%
Q4 FY22Q/Q Change
Total Assets
109.2B
↑ 1.94%
Total Liabilities
63.1B
↑ 0.87%
Q1 FY23Q/Q Change
Total Assets
107.8B
↓ 1.25%
Total Liabilities
60.9B
↓ 3.5%
Q2 FY23Q/Q Change
Total Assets
104.5B
↓ 3.09%
Total Liabilities
65.7B
↑ 7.94%
Q3 FY23Q/Q Change
Total Assets
106.7B
↑ 2.16%
Total Liabilities
65.4B
↓ 0.46%
Q4 FY23Q/Q Change
Total Assets
106.7B
↓ 0.05%
Total Liabilities
69.0B
↑ 5.52%
Q1 FY24Q/Q Change
Total Assets
106.7B
↑ 0.0%
Total Liabilities
69.0B
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
10.9B
↑ 69.41%
Investing Cash Flow
4.3B
↑ 61.03%
Financing Cash Flow
-13.2B
↑ 31.52%
FY19Y/Y Change
Operating Cash Flow
13.4B
↑ 23.05%
Investing Cash Flow
-2.6B
↓ 160.94%
Financing Cash Flow
-8.9B
↓ 32.67%
FY20Y/Y Change
Operating Cash Flow
10.3B
↓ 23.71%
Investing Cash Flow
-9.4B
↑ 259.19%
Financing Cash Flow
-2.8B
↓ 68.04%
FY21Y/Y Change
Operating Cash Flow
14.1B
↑ 37.61%
Investing Cash Flow
-16.6B
↑ 75.32%
Financing Cash Flow
2.6B
↓ 191.56%
FY22Y/Y Change
Operating Cash Flow
19.1B
↑ 35.34%
Investing Cash Flow
-5.0B
↓ 70.04%
Financing Cash Flow
-9.1B
↓ 451.68%
FY23Y/Y Change
Operating Cash Flow
13.0B
↓ 31.89%
Investing Cash Flow
-14.1B
↑ 183.93%
Financing Cash Flow
-4.8B
↓ 47.25%
Q4 FY22Q/Q Change
Operating Cash Flow
4.4B
↓ 20.92%
Investing Cash Flow
-1.7B
↑ 81.7%
Financing Cash Flow
-1.6B
↓ 42.49%
Q1 FY23Q/Q Change
Operating Cash Flow
1.3B
↓ 69.77%
Investing Cash Flow
-2.4B
↑ 34.95%
Financing Cash Flow
-2.1B
↑ 32.18%
Q2 FY23Q/Q Change
Operating Cash Flow
3.7B
↑ 176.62%
Investing Cash Flow
-11.4B
↑ 385.08%
Financing Cash Flow
3.8B
↓ 282.96%
Q3 FY23Q/Q Change
Operating Cash Flow
7.7B
↑ 108.34%
Investing Cash Flow
-334.0M
↓ 97.08%
Financing Cash Flow
-4.3B
↓ 213.6%
Q4 FY23Q/Q Change
Operating Cash Flow
246.0M
↓ 96.81%
Investing Cash Flow
53.0M
↓ 115.87%
Financing Cash Flow
-2.2B
↓ 47.41%

Technicals Summary

Sell

Neutral

Buy

Merck & Co. Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Merck & Co. Inc.
Merck & Co. Inc.
0.7%
21.56%
18.37%
72.56%
57.06%
Eli Lilly And Company
Eli Lilly And Company
14.46%
45.15%
94.58%
283.59%
675.62%
Johnson & Johnson
Johnson & Johnson
-3.84%
-6.66%
-9.54%
-12.07%
3.34%
Abbvie Inc
Abbvie Inc
2.98%
7.64%
20.09%
43.93%
110.37%
Amgen Inc.
Amgen Inc.
-2.39%
6.91%
35.63%
24.83%
70.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Merck & Co. Inc.
Merck & Co. Inc.
148.13
148.13
0.1
8.65
0.05
0.1
0.02
15.94
Eli Lilly And Company
Eli Lilly And Company
128.49
128.49
1.43
13.77
0.51
0.13
0.01
14.23
Johnson & Johnson
Johnson & Johnson
21.84
21.84
0.89
10.63
0.24
0.08
0.03
29.09
Abbvie Inc
Abbvie Inc
49.91
49.91
0.45
11.24
0.56
0.08
0.04
4.54
Amgen Inc.
Amgen Inc.
42.9
42.9
2.39
19.46
0.73
0.05
0.03
9.36
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$333.9B
57.06%
148.13
3.76%
Eli Lilly And Company
Eli Lilly And Company
Buy
$824.3B
675.62%
128.49
17.08%
Johnson & Johnson
Johnson & Johnson
Buy
$353.2B
3.34%
21.84
44.92%
Abbvie Inc
Abbvie Inc
Buy
$296.1B
110.37%
49.91
11.02%
Amgen Inc.
Amgen Inc.
Buy
$161.3B
70.38%
42.9
12.74%

Institutional Holdings

  • Vanguard Group Inc

    9.60%
  • BlackRock Inc

    8.17%
  • State Street Corporation

    4.64%
  • Wellington Management Company LLP

    3.41%
  • Geode Capital Management, LLC

    2.23%
  • FMR Inc

    2.06%

Corporate Announcements

  • Merck & Co. Inc. Dividends March,2024

    In the quarter ending March,2024. Merck & Co. Inc. has declared dividend of $0.77

    Read More

Company Information

Merck & Co., Inc. is an American multinational pharmaceutical company. The corporation conducts business outside of the United States and Canada under Merck Sharp & Dohme (MSD). It was founded as an American subsidiary of the German pharmaceutical company Merck & Co. in 1891. The company was given this name in honour of the Merck family. Merck acquired the Livogen trademark from Glaxo India for Rs 8 crore in 2000 - well over the market value. According to the company, Rofecoxib will be distributed in the Philippines via a co-marketing arrangement with the local pharmaceutical business Kopran. When Biochem Pharmaceutical Industries Ltd purchased Taloja in 2004, the firm spent a total of Rs 100 million, making it the most costly acquisition the company had made then. On March 27, 2002, a decision was made to rename the company from E Merck (India) Ltd to Merck Ltd, and the company was officially constituted on that day. This increased the firm's capacity for the manufacturing of Bulk Drugs by 33 tonnes in 2006, increasing the company's overall production capacity to 351 tonnes. In 2020, the pharmaceutical business will have six blockbuster medications or products with more than $1 billion in revenue. An antibody used to treat cancer is Keytruda, estimated to make $14.3 billion this year. Varivax is supposed to make $3.9 billion each, and Gardasil will make $1.4 billion each. Currently Merck & Co. Inc. has a market cap of $333.93 Billion. It has a P.E ratio of 144.81. The shares of Merck & Co. Inc. are trading at $130.2. .

Organization
Merck & Co. Inc.
Employees
70000
CEO
Mr. Robert M. Davis J.D.
Industry
Health Technology

FAQs